Home | Publications | Diseases | Diabetes place holder
place holder place holder

Diabetes

Diabetes & Obesity

A Competitor Analysis

Publication Date   March 2007
Publisher   La Merie
Product Type   Brief
Pages   71
ISBN Number   not applicable
Product Code   LME041
Ask a question about this product?

Price £675.00

approximately: $1,261 | €856

Summary


The present Competitive Intelligence Report provides a competitor evaluation in the field of molecules used to treat diabetes and obesity as of March 2007. The competitor evaluation of Molecules to treat diabetes compiles parts of our Competitor Analysis Series which previously have been published in R&D Pipeline News, vol.3, 2007. Competitor projects are listed in a tabular format providing Information on:

Information is provided on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Content


  • Chapter 1: Obesity
    • CB1
    • Selective 5-HT2c Receptor Agonists
    • Selective 5-HT6 Receptor Antagonists
    • Monoamine-related Mechanism of Action
    • Pro-opiomelanocortin (POMC) & Melanin-related Mechanism of Action
    • Protein tyrosine phosphatase-1B (PTP-1B) Inhibitors
    • PPAR Agonists
    • Thyroid Hormone Receptor Modulators
    • SGLT-2 Inhibitors
    • Microsomal triglyceride transfer protein inhibitors
    • Various
    • Anti-Obesity peptides
    • Anti-Obesity Biologics
  • Chapter II: Insulin
    • Insulin Market: Sales 2006
    • Inhaled Insulin
    • Nasal Insulin
    • Transdermal Insulin
    • Oral Insulin
    • Engineered Insulin
    • Long-Acting Insulin
    • Follow-On Insulin
  • Chapter III: PPAR Agonists
    • 1st Generation PPAR Gamma Agonists
    • Next Generation PPAR Gamma Agonists
    • PPAR Alpha Agonists (Fibrate Type)
    • PPAR Alpha Agonists
    • Discontinued PPAR Alpha Agonists
    • Dual PPAR Alpha And Gamma Agonists
    • Discontinued Dual PPAR Alpha / Gamma Agonists
    • Triple PPAR Alpha, Gamma & Delta (Pan) Agonists
  • Chapter IV: DPP-IV
    • DPP-IV
    • DPP-IV Discontinued or No Further Activities
  • Chapter V: GLP-1
  • Chapter VI: SGLT Inhibitors
  • Chapter VII: Emerging Diabetes Drugs